Emulsions for ocular applications containing lifitegrast and semifluorinated alkanes
A stable emulsion combining semifluorinated alkanes and lifitegrast in an oil-in-water nanoemulsion addresses the challenge of treating both forms of dry eye disease, offering effective and convenient treatment with reduced irritation.
Patent Information
- Application Number
- PCT/EP2026/062972
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Current ophthalmic compositions cannot stabilize semifluorinated alkanes and lifitegrast in a single formulation due to their immiscibility and density differences, making it challenging to treat both aqueous-deficient and evaporative dry eye disease effectively.
An emulsion is formulated with an organic phase containing semifluorinated alkane and an aqueous phase with lifitegrast, stabilized by a surfactant, maintaining less than 29% by weight of the organic phase, which is an oil-in-water nanoemulsion with specific surfactant combinations and densities to ensure stability.
The emulsion provides stable, effective treatment for both types of dry eye disease with reduced irritation, allowing a single composition to address both aqueous-deficient and evaporative DED, enhancing patient convenience and reducing application frequency.
Smart Images

Figure IMGF000003_0001 
Figure IMGF000006_0001 
Figure IMGF000021_0001
Abstract
Description
EMULSIONS FOR OCULAR APPLICATIONS CONTAINING LIFITEGRAST AND SEMIFLUORINATED ALKANES
[0001] This application claims the benefit of European Patent Application EP25174597.2, filed May 6th 2025, the complete contents of which are incorporated herein by reference.
[0002] The present invention relates to emulsions for ocular applications containing lifitegrast, or a pharmaceutically acceptable salt thereof, and at least one semifluorinated alkane, such as F6H8, their use in methods for treating ocular disorders, and methods for their manufacture.BACKGROUND
[0003] Keratoconjunctivitis sicca, also known as dry eye disease (DED), is a multifunctional disorder of the tear film and ocular surface, which results in discomfort, visual disturbance, and often even in ocular surface damage. Secondary diseases whose development may be triggered by dry eye disease include filamentary keratitis, microbial keratitis, corneal neovascularisation, and ocular surface keratinisation.
[0004] Two major categories of dry eye disease are distinguished today, which are aqueous-deficient DED and evaporative DED. Evaporative DED is associated with increased evaporative loss of the tear film and can develop as a result of diverse root causes including meibomian gland disease, eyelid aperture disorders, blink disorders (as in Parkinson disease) or ocular surface disorders (as in allergic conjunctivitis).
[0005] Typically, ophthalmic compositions for treatment of ocular disorders, including DED, are administered as eye drops, with one or more drops of the composition being applied to an eye of the subject suffering from or susceptible to ocular disorders one or more times per day, although the frequency of administration of such compositions may be dependent on multiple factors, including the makeup of the particular composition.
[0006] Aqueous-deficient DED and evaporative DED are not mutually exclusive, and a large percentage of DED patients suffer from both conditions. Providing a single ophthalmic composition suitable to address both aqueous-deficient DED and evaporative DED would be of significant benefit to such patients, who may otherwise require two separate treatments, one for each type of DED.
[0007] Semifluorinated alkanes are an example of agents that may treat DED, specifically evaporative DED. Semifluorinated alkanes work to protect the surface of the eye by stabilizing the tear film on the surface of the eye, thereby reducing tear evaporation. Semifluorinated alkanes have recently been approved by the FDA against evaporative DED. For example, perfluorohexyloctane (F6H8) has been approved as Miebo™ for the treatment of evaporative DED. In Miebo™, F6H8 is provided as a water-free sterile ophthalmic solution containing 100% F6H8.
[0008] For aqueous-deficient DED, aqueous-based systems are established for treatment. For example, aqueous-based systems comprising hydrophilic, lubricating and / or mucoadhesive polymers have shown clinical efficacy against aqueous deficient DED. Aqueous-based systems are particularly suitable in the treatment of aqueous-deficient DED due to their wetting properties i.e. their ability to maintain contact with the surface of the eye. Aqueous-based systems also have the ability to carry aqueous-compatible pharmaceutical actives suitable for treating DED.
[0009] Lifitegrast (the active ingredient of Xiidra™) is a novel small molecule lymphocyte function-associated antigen 1 (LFA-1) antagonist that has recently been approved by the US Food and Drug Administration for the treatment of signs and symptoms of DED. It has the following structure:
[0010] The current understanding of the mechanism of action of lifitegrast is that it decreases T cell-mediated inflammation associated with dry eye disease by blocking the interaction between the integrin LFA-1 and intercellular adhesion molecule 1 (ICAM-1), thereby preventing inflammatory cell activation and migration.
[0011] Lifitegrast is provided as an aqueous-based solution in Xiidra. In particular, Xiidra is a 5.0% ophthalmic solution in single-dose units and administered to each eye twice daily (b.i.d.; ~12 hours apart).
[0012] Despite the success of Xiidra in meeting the needs of many patients suffering from DED, it would be beneficial to combine the therapeutic effects of semifluorinated alkanes and lifitegrast in the same single ophthalmic composition. However, lifitegrast is currently provided in an aqueous-based solution, and aqueous-based solutions are immiscible with semifluorinated alkanes. Semifluorinated alkanes are very hydrophobic, so do not mix well with water, meaning that mixtures of semifluorinated alkanes and water are unstable and separate readily. As a result, semifluorinated alkanes cannot be readily added to existing aqueous-based systems to provide stable compositions. Additionally, semifluorinated alkanes have much higher densities than water, which creates further instability problems when attempting to mix both components in a single composition. For example, the semifluorinated alkane F6H8 has a density of 1.334 g / cm3, far higher than that of water (1 g / cm3). Currently, there is no marketed formulation for ocular applicationsthat combines the effects of semifluorinated alkanes with those of aqueous-based systems and lifitegrast.
[0013] There is therefore a need for ophthalmic compositions with adequate stability that combine the benefits of semifluorinated alkanes with aqueous-based systems and lifitegrast.SUMMARY OF THE INVENTION
[0014] The invention provides an emulsion for ocular applications, comprising (a) an organic phase comprising at least one semifluorinated alkane; (b) an aqueous phase comprising lifitegrast, or a pharmaceutically acceptable salt thereof; and (c) a surfactant; wherein the emulsion comprises less than 29% by weight of the organic phase. The semifluorinated alkane is preferably F6H8.
[0015] These and other features, aspects, and advantages of the invention will be apparent from a reading of the following.Definitions
[0016] Definitions of certain terms as used in this application are provided below. Unless defined otherwise, all technical and scientific terms used herein have the normal and common meaning that would be commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0017] As used herein, the term “about” means approximately, in the region of, roughly, or around. The term “about” in relation to a numerical value x is optional and means, for example, x ± 5%. Numerical values disclosed with the term “about” include the specifically identified value. For example, “about 100” means a number ranging from 95 to 105, including 95, 100, and 105.
[0018] As used herein, “administration” of a compound or composition to a patient refers to any route of introducing or delivering the compound or composition to a subject. Administration includes self-administration and the administration by another.
[0019] As used herein, a “condition,” “disorder,” or “disease” refers to any unhealthy or abnormal state.
[0020] As used herein, a composition is “free” of a component when it comprises no detectable amount of the component.
[0021] A used herein, a "surfactant" is a surface-active substance which is capable of reducing the surface tension between an organic and aqueous phase by positioning itself at the interface between these two phases. This is achieved by the amphiphilic molecular structure of the surfactant, which has at least one polar (hydrophilic) group and at least one non-polar (lipophilic) group. Thus, surfactants are soluble in both the organic and aqueous phases. The part of the surfactant that is more soluble in the organic phaseprojects into the organic phase, and the part of the surfactant that is more soluble in the aqueous phase projects into the aqueous phase, thus lowering the interfacial tension between the two phases.
[0022] As used herein, the term “consists essentially of” means that, in addition to the mandatory ingredients, specific further ingredients can be present, namely those not materially affecting the essential characteristics of the composition or component in question. Compositions or components herein which “consist essentially of” the specified ingredients may consist only of the specified ingredients, with no other ingredients present.
[0023] As used herein, “osmoprotectants” are small molecules that act as osmolytes and help protect cells and organisms from osmotic stress. Chemically, osmoprotectants can be divided into three types: betaines and allied compounds, polyols and sugars (e.g. glycerol, mannitol and trehalose), and amino acids. Betaines are methyl derivatives of glycine in which the nitrogen atom is fully methylated, i.e. they are quaternary ammonium compounds.
[0024] As used herein, the term "viscosity" means dynamic viscosity, which is also referred to as absolute viscosity. Unless otherwise stated, the viscosity refers to the viscosity of the composition prior to application to the eye.
[0025] As used herein, “semifluorinated alkanes” are linear or branched alkanes having fluorine in place of some of the hydrogen atoms of the corresponding non-fluorinated alkane. In particular, semifluorinated alkanes are compounds composed of at least one perfluorinated hydrocarbon segment and at least one non-fluorinated hydrocarbon segment. According to a nomenclature used herein, the semifluorinated alkanes may be referred to as FnHm, wherein F refers to the perfluorinated hydrocarbon segment (F-segment), H refers to the non-fluorinated hydrocarbon segment (H-segment), and n and m refer to the number of carbon atoms of those segments, respectively. For example, F6H8 is used to refer to perfluorohexyloctane.
[0026] This type of nomenclature is typically used for compounds wherein the perfluorinated carbons are bonded together to form a single linear F-segment and the non-fluorinated carbons are bonded together to form a single linear H-segment. Typically, the perfluorinated F-segment is attached to an end of the non-fluorinated H-segment, i.e., it is attached to C1 , so that the overall molecule is linear. However, a minority of branched compounds, wherein two linear (F and H) segments are joined at a different position such as C2, may be present. In the case of perfluorohexyloctane (F6H8), the perfluorohexyloctane comprises 95% (w / w) or more of 1 -perfluorohexyloctane, preferably 98% (w / w) or more, more preferably 99.5% (w / w) or more. Preferably, the balance is 2-perfluorohexyloctane.
[0027] As used herein, the term “mineral oil” refers to oil derived from refined petroleumbased hydrocarbons. It typically contains mineral oil saturated hydrocarbons (MOSH) such as paraffins and naphthenes, and mineral oil aromatic hydrocarbons (MOAH), such as alkylated mono- and poly-aromatic rings. Mineral oil is distinct from vegetable or animal derived oils, which have a biological origin.
[0028] As used herein, “triglycerides” are fatty acid esters of glycerol. As used herein, "medium chain triglycerides" or “MCTs” are fatty acid esters of glycerol with a chain length of 6 to 12 carbon atoms. As used herein, "long chain triglycerides" are fatty acid esters of glycerol with a chain length of 14 to 18 carbon atoms.
[0029] As used herein, the term “nanoemulsion” refers to an emulsion in which organic phase droplets dispersed in a continuous aqueous phase have a Z-average droplet diameter in the nanometer range (e.g. between 20 and 1000 nm).
[0030] As used herein, “Z-average” refers to the intensity-weighted mean hydrodynamic size of a collection of droplets.
[0031] As used herein, “polydispersity” refers to a measure of the width of the size distribution of droplets, and is conventionally expressed as the polydispersity index (PDI). A polydispersity index of greater than 0.7 indicates that the sample has a very broad size distribution and a reported value of 0 means that size variation is absent, although values smaller than 0.05 are rarely seen, other than with highly monodisperse standards.
[0032] As used herein, “Hydrophilic-Lipophilic Balance” (HLB) refers to a measure of a surfactant's tendency to be water-soluble or oil-soluble. HLB values range from 0 to 20, with lower values indicating greater lipophilicity (oil-soluble) and higher values indicating greater hydrophilicity (water-soluble). The HLB value of many surfactants can readily be found in the literature. If calculation of the HLB value for a surfactant is required, Griffin’s method can be used, in which the HLB value is calculated according to the following equation: / Mh\HLB = 20 —\M Jwhere Mh is the molecular mass of the hydrophilic portion of the surfactant molecule, and M is the molecular mass of the whole surfactant molecule.
[0033] As used herein, the terms “patient,” “subject,” “individual,” and the like, as used herein, are interchangeable and refer to any animal, which may be a human or a nonhuman animal. Compositions of the invention are particularly suited to use in humans and so the patient is preferably a human.
[0034] As used herein, the terms “prevention” of or “preventing” a disorder, disease, or condition refers to reducing the seventy and / or reducing the occurrence of the disorder, disease, or condition in a treated sample relative to an untreated control sample, andincludes delaying onset and / or progression of the disorder or condition relative to the untreated control sample.
[0035] As used herein, the term “ocular disorder” refers to any of the signs, symptoms, and / or underlying cause(s) of any physiological disorder that affects the eye or vision.
[0036] As used herein, the term “treat,” “treating,” or “treatment,” when used in connection with a disorder or condition, includes any effect, e.g., lessening, reducing, modulating, ameliorating, or eliminating, that results in the improvement of the disorder or condition. Improvements in or lessening the seventy of any symptom of the disorder or condition can be readily assessed according to standard methods and techniques known in the art.
[0037] As used herein, a “pharmaceutically acceptable salt” is a salt that is suitable for use in contact with tissues of humans without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N+(Ci-4alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Examples of pharmaceutically acceptable acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2 hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2 naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3 phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p toluenesulfonate, undecanoate, valerate salts, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.
[0038] As will be understood by one of ordinary skill in the art, each range disclosed herein includes all possible subranges as well as individual numerical values within that range, including endpoints. As a non-limiting example, a range of “0.001% to 0.02%” includes the end-points of 0.001% and 0.02%, and would be understood to specifically disclose subranges such as “0.004% to 0.01%,” “0.005% to 0.02%,” etc., as well as allindividual numbers within the disclosed range, for example, 0.001%, 0.004%, 0.005%, 0.01%, 0.02%, etc.DETAILED DESCRIPTION
[0039] The present inventors have surprisingly discovered that stable ophthalmic compositions may be provided in the form of emulsions containing an organic phase comprising at least one semifluorinated alkane, and an aqueous phase containing lifitegrast. The emulsions are for ocular applications, i.e. , they are suitable for application to the human eye for the treatment of an ocular disorder such as dry eye disease, preferably without causing serious irritation or other adverse effects.
[0040] From a clinical perspective, it is highly beneficial to be able to provide a stable ophthalmic composition that contains both a semifluorinated alkane and lifitegrast. Without wishing to be bound by theory, it is believed that the semifluorinated alkane provides its own ocular disorder treatment and / or prevention effect on evaporative DED (thus intersecting the disease cycle with effects on both inflammation and tear evaporation), whilst the lifitegrast decreases T cell-mediated inflammation associated with DED. The compositions may therefore be suitable for providing effective treatment of DED, that beneficially combines the therapeutic effects of semifluorinated alkanes and lifitegrast.
[0041] In addition, the aqueous phase provides inter alia good wetting properties suitable for treating aqueous-deficient DED. The compositions may therefore also be suitable for providing effective treatment of both aqueous-deficient DED and evaporative DED, meaning that patients with mixed-type DED may only need to apply one composition in order to treat both types of DED.
[0042] Emulsions for ocular applications which contain semifluorinated alkanes and lifitegrast have not previously been described. Providing an emulsion rather than an aqueous-based system is advantageous because emulsions often produce less itching, burning or other unpleasant side effects upon contact with the eye compared to aqueous solutions.
[0043] Formulating an emulsion for ocular applications presents further challenges beyond the incompatibility of semifluorinated alkanes and water. For example, the eye is a particularly sensitive location for topical administration, so measures must be taken to minimize irritation to the eye and provide compositions which are acceptable for application to, and interaction with, the surface of the eye. This includes ensuring that the emulsions can be easily applied to the eye, and that the emulsions spread easily across the surface of the eye to avoid the need to rub the medicament into the eye, which is highly undesirable.
[0044] The invention provides an emulsion for ocular applications, comprising (a) an organic phase comprising at least one semifluorinated alkane; (b) an aqueous phase comprising lifitegrast, or a pharmaceutically acceptable salt thereof; and (c) a surfactant; wherein the emulsion comprises less than 29% by weight of the organic phase.
[0045] The emulsions of the invention are physically stable on visual inspection, meaning that the organic phase and the aqueous phase do not separate, and remain stable for extended period of time. The inventors’ finding of the disclosed stable ophthalmic emulsions is particularly surprising in view of the density difference between semifluorinated alkanes and water, which makes formulating stable emulsions of semifluorinated alkanes and available aqueous-based systems for lifitegrast challenging.
[0046] The emulsion may comprise less than about 25% by weight of the organic phase, for example less than about 20% by weight or less than about 15% by weight. The emulsion may comprise about 0.05% to about 10% by weight of the organic phase, for example about 2% to about 8% by weight of the organic phase, for example about 5% by weight of the organic phase.
[0047] The emulsion will therefore typically be an oil-in-water emulsion i.e. the aqueous phase may form the outer phase of the emulsion, the organic phase may form the inner phase of the emulsion, and the organic phase may be dispersed as droplets in the aqueous phase.
[0048] Oil-in-water emulsions become unstable when organic phase droplets finely dispersed in an aqueous phase come into contact and aggregate. This process limits the stability of the emulsion during storage, and proceeds more slowly the more viscous the continuous phase of the emulsion is. However, surprisingly, the inventors have found that the organic phase droplets dispersed in the aqueous phase in the described emulsions do not coalesce.
[0049] Therefore, the described emulsions are stable, even at low viscosities. It is desirable for ophthalmic compositions that are intended to be provided as eye drops to have low viscosities because they spread readily on the surface of the eye, so require little or no mechanical assistance for distribution. A further advantage is that low viscosity compositions create only a slight foreign body sensation in the eye on application, so are more tolerable for the patient. In addition, lower viscosity compositions are easier to dispense from dosing containers, particularly eye drop dispensing containers.
[0050] In addition, surprisingly, the inventors have found that emulsions for ocular applications can be provided with a relatively low amount of organic phase, and therefore a relatively low amount of semifluorinated alkane. This is advantageous because a relatively large aqueous phase allows for versatility in the amount of, and type of, aqueous-compatible components that can be included in the emulsion. Thesecomponents include lifitegrast, potentially other active pharmaceutical ingredients for treating ocular disorders, and other aqueous-compatible components that have beneficial effects on the eye, such as hyaluronic acid. A particular advantage of the relatively large aqueous phase is the ability to increase the loading of lifitegrast in the emulsion. In turn, this may allow for the amount of emulsion that needs to be applied to the eye for effective treatment to be reduced, or for the frequency of administration to be reduced.
[0051] Without wishing to be bound by theory, a relatively low amount of semifluorinated alkane is believed to provide benefits in treating DED because the semifluorinated alkane treats DED by forming a thin film on the eye to prevent evaporation of water. It is therefore advantageous for ocular applications to be able to form a stable emulsion of an aqueous phase containing lifitegrast and a semifluorinated alkane containing a low amount of semifluorinated alkane.
[0052] The emulsion may be a nanoemulsion. Nanoemulsions are particularly stable because the organic phase droplets have a reduced propensity to aggregate. The Z-average size of the inner organic phase droplets may be in the range of from about 40 to about 500 nm, for example from about 70 to about 400 nm, for example from about 70 to about 220 nm. Nanoemulsions with a Z-average size of less than about 220 nm are advantageous because they can be subjected to filter sterilization.Surfactant
[0053] The surfactant is suitable for inclusion in an emulsion for ophthalmic applications, and is therefore an ophthalmically compatible surfactant.
[0054] The surfactant may be selected from an anionic surfactant, a cationic surfactant, a nonionic surfactant, an amphoteric surfactant, or a combination thereof. The surfactant may be selected from a cationic surfactant, a nonionic surfactant, an amphoteric surfactant, or a combination thereof.
[0055] Preferably, the surfactant is selected from a cationic surfactant, a nonionic surfactant, or a combination thereof. As described in the examples, the inventors have surprisingly found that using cationic and / or nonionic surfactants provides emulsions which are more stable than when using amphoteric surfactants, such as lecithins. Amphoteric surfactants, such as lecithins, are commonly used in emulsions, and it was unexpected that cationic and nonionic surfactants would provide improved stability relative to the use of amphoteric surfactants. This further highlights the challenges and unpredictability faced by the inventors when aiming to provide stable emulsions containing semifluorinated alkanes and lifitegrast.
[0056] The surfactant may be selected from ethylene oxide-formaldehyde-p-octylphenol copolymer (tyloxapol), polyethoxylated sorbitan fatty acid esters such as polysorbate 20, polysorbate 60 or polysorbate 80, poloxamers such as poloxamer 188, a lecithin, abetaine, benzalkonium chloride, cetyltrimethylammonium bromide, and cetalkonium chloride, or a combination thereof. Preferably, the surfactant is selected from ethylene oxide-formaldehyde-p-octylphenol copolymer (tyloxapol), polyethoxylated sorbitan fatty acid esters such as polysorbate 20, polysorbate 60 or polysorbate 80, poloxamers such as poloxamer 188, benzalkonium chloride, cetyltrimethylammonium bromide, and cetalkonium chloride, or a combination thereof. More preferably, the surfactant is selected from ethylene oxide-formaldehyde-p-octylphenol copolymer, poloxamers (amongst which poloxamer 188 is preferred), and cetalkonium chloride, or a combination thereof.
[0057] The surfactant may be a combination of a cationic surfactant and a nonionic surfactant. For example, the surfactant may be a combination a nonionic surfactant with cetalkonium chloride, for example a combination of (a) ethylene oxide-formaldehyde-p-octylphenol copolymer or a polyethoxylated sorbitan fatty acid ester such as polysorbate 80 and (b) cetalkonium chloride.
[0058] The emulsion may comprise a surfactant with an HLB value of at least 5, preferably at least 10, more preferably at least 12. Similarly, if the emulsion contains more than one surfactant, each surfactant in the emulsion may have an HLB value of at least 5, preferably at least 10, more preferably at least 12. It has unexpectedly been found that the use of a surfactant with an HLB value of at least 5 provides emulsions that have greater stability than those where the surfactant has a lower HLB value. Similarly, the use of a surfactant with an HLB value of at least 10 provides emulsions with even greater stability than those where the surfactant has an HLB value of at least 5 but less than 10.
[0059] The total amount of surfactant in the emulsion may be in the range of from about 0.05% to about 5% by weight, for example from about 0.1% to about 3% by weight, or from about 0.1% to about 2% by weight. It is beneficial to minimize the amount of surfactant in emulsions for ocular applications because surfactants can cause irritation to the eye and a particular advantage of the emulsions of the present invention is the ability to form a stable emulsion containing a semifluorinated alkane and an aqueous phase which contains a very low amount of surfactant.
[0060] The emulsion may comprise about 2% to about 8% by weight of the organic phase and the total amount of surfactant in the emulsion may be in the range of from about 0.1 % to about 4% by weight, for example in the range of from about 0.1% to about 2% by weight.Aqueous phase
[0061] The aqueous phase comprises lifitegrast, or a pharmaceutically acceptable salt thereof. The lifitegrast in the composition may be present in the form of a pharmaceutically acceptable salt, but is most preferably present in the form of lifitegrast free acid. When lifitegrast is present in the form of a pharmaceutically acceptable salt, thepharmaceutically acceptable salt is preferably selected from sodium, potassium, arginine, and tris(hydroxymethyl)aminomethane salts, more preferably a sodium salt. Where a salt is used, concentrations or amounts of I ifitegrast disclosed herein are calculated according to the corresponding quantity of lifitegrast free acid, i.e. on a free acid basis.
[0062] The emulsion may comprise about 0.05% to about 10% by weight of lifitegrast or a pharmaceutically acceptable salt thereof, on a free acid basis. For example, the emulsion may comprise about 2% to about 8% by weight of lifitegrast or a pharmaceutically acceptable salt thereof, on a free acid basis, for example about 5% by weight of lifitegrast or a pharmaceutically acceptable salt thereof, on a free acid basis. These amounts of lifitegrast are suitable to provide effective therapy for DED, particularly when administered as eye drops.
[0063] The aqueous phase may comprise hyaluronic acid and / or hyaluronate. Hyaluronic acid is a naturally occurring highly viscous glycosaminoglycan consisting of glucose derivatives D-glucuronic acid and N-acetyl-D-glucosamine. Depending on the extraction method, the molecular weight Mw of the hyaluronic acid may be in the range of 50,000 to 10,000,000 g / mol. Hyaluronic acid is a component of the extracellular matrix of vertebrates and, in particular, a natural component of human eye fluids. The hyaluronic acid may be obtained from animal or vegetable sources or may be produced synthetically or semi-synthetically.
[0064] The hyaluronate may be selected from the group consisting of sodium hyaluronate, potassium hyaluronate, zinc hyaluronate, and mixtures thereof. Preferably, the hyaluronate is sodium hyaluronate.
[0065] The hyaluronic acid and / or hyaluronate may have a molecular weight Mw of 50,000 to 10,000,000 g / mol, or 100,000 to 5,000,000 g / mol, preferably 250,000 to 1,000,000 g / mol.
[0066] The emulsion may comprise hyaluronic acid and / or hyaluronate in an amount of at least about 0.01 % by weight, for example at least 0.15% by weight, or at least 0.2% by weight. The emulsion may comprise hyaluronic acid and / or hyaluronate, preferably sodium hyaluronate, in an amount of about 0.1% to about 5% by weight, for example about 0.1% to about 2% by weight, or about 0.15% to about 0.35% by weight.
[0067] The emulsion may also comprise an osmoprotectant. The emulsion may comprise from about 0.5% to about 7% osmoprotectant by weight of the emulsion. The osmoprotectant may comprise dextrose, glycerin, propylene glycol, sorbitol, mannitol, urea, polyethylene glycol, boric acid, magnesium sulfate, zinc sulfate, sodium chloride, potassium chloride, calcium chloride, sodium sulfate, sodium hydrogen phosphate, trisodium citrate, trisodium phosphate, and mixtures thereof. Preferably, the osmoprotectant is glycerin. The emulsion may comprise from about 0.5% to about 5% byweight of glycerin, preferably from about 0.5% to about 2% by weight. The emulsion may have an osmolality of about 250 to about 350 mOsm / kg.
[0068] The aqueous phase may comprise a preservative. The preservative may be selected from sodium thiosulfate, benzalkonium chloride, cetrimonium, sodium perborate, stabilized oxychloro complex, a composition containing boric acid, sorbitol, propylene glycol, and zinc chloride, polyquaternium-1 , chlorobutanol, edetate disodium, polyhexamethylene biguanide, or combinations thereof, preferably wherein the preservative is sodium thiosulfate. The preservative may be present in an amount of from about 0.1% to about 0.5% by weight of the emulsion, for example from about 0.2% to about 0.4% by weight of the emulsion, for example about 0.3% by weight of the emulsion.
[0069] The aqueous phase may comprise sodium hydroxide, and optionally also hydrochloric acid, for pH adjustment.
[0070] The pH of the emulsion is typically between about 6 and about 9. The aqueous phase may comprise a buffer system to maintain the pH of the emulsion between 6 and 9. Typically, the buffer system may be a phosphate or citrate buffer.Organic phase
[0071] The organic phase of the disclosed emulsions comprises at least one semifluorinated alkane. The organic phase may comprise at least 90% by weight semifluorinated alkane, for example the organic phase may consist essentially of semifluorinated alkane.
[0072] The at least one semifluorinated alkane may comprise F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof. The at least one semifluorinated alkane may comprise F4H5, F4H6, F5H6, F5H7, F6H6, F6H7, F6H8, F6H10 or any combination thereof. The at least one semifluorinated alkane may comprise F4H5, F6H8, or a combination thereof. The at least one semifluorinated alkane may comprise F4H5 and the organic phase may be substantially free of other semifluorinated alkanes. The at least one semifluorinated alkane may comprise F6H8, F6H10 or a combination thereof. Preferably, the at least one semifluorinated alkane comprises F6H8 and, more preferably, the organic phase may be substantially free of other semifluorinated alkanes. As used herein, a composition may be “substantially free of other semifluorinated alkanes” when the other semifluorinated alkanes are present at a relative amount of 2% (w / w) or less, preferably 1% (w / w) or less, or more preferably 0.5% (w / w) or less based on the total amount of semifluorinated alkanes in the composition.
[0073] The organic phase may comprise at least 90% by weight semifluorinated alkane. The organic phase may consist essentially of semifluorinated alkane, and, preferably, the semifluorinated alkane may be F6H8.
[0074] The organic phase may comprise at least 90% by weight F6H8, for example the organic phase may consist essentially of F6H8. F6H8 may be the only semifluorinated alkane in the organic phase.
[0075] In addition to the at least one semifluorinated alkane, the organic phase may comprise at least one other ophthalmically acceptable oil, preferably wherein the ophthalmically acceptable oil is selected from triglycerides and mineral oil. The organic phase may consist essentially of at least one semifluorinated alkane, preferably F6H8, and at least one ophthalmically acceptable oil selected from triglycerides and mineral oil.
[0076] Triglycerides may include medium chain triglycerides and long chain triglycerides. Preferably, the ophthalmically acceptable oil is a medium chain triglyceride. Medium chain triglycerides can advantageously prevent evaporation of the aqueous component of the emulsion, thereby preventing or reducing drying of the tear film or emulsion after application to the eye.
[0077] Suitable triglycerides are available in the form of synthetic, semisynthetic or natural oils, such as olive oil, palm oil, almond oil, coconut oil or mixtures thereof. Preferred triglycerides are obtainable from coconut oil. Such medium chain triglycerides are prepared, for example, from the oil of the endosperm of Cocos nucifera L. (the solid dried part), or E / asesis guineensis Jacq. Medium chain triglycerides that may be used include neutral oils, for example those obtainable under the trade names Myritol®312, Myritol®318, or Myritol®331 , commercially available from Cognis Ltd., Japan. Medium chain triglycerides of the type described in the European Pharmacopoeia, European Pharmacopoeia 5.0, 01 / 2010:0868, page 3471, Triglyceridea satnata media may also be used.
[0078] The medium chain triglyceride may be formed from at least 80 wt%, preferably at least 90 wt%, and more preferably at least 95 wt%, C8-C12-fatty acids, preferably C8-C10-fatty acids, based on the total weight of the fatty acids in the medium chain triglyceride. The medium chain triglyceride may be a saturated medium chain triglyceride. The saturated medium chain triglyceride may be formed from at least 80 wt%, preferably at least 90 wt%, and more preferably at least 95 wt%, saturated C8- and C10-fatty acids based on the total weight of the fatty acids in the medium chain triglyceride.
[0079] Other suitable medium chain triglycerides are commercially available under the trade names Acomed®, Captex®, Neobee®M5F, Miglyol®810, Miglyol®812, Mazole®, or Sefsol®860.
[0080] Particularly preferred medium chain triglycerides are caprylic-capric acid triglycerides, i.e. a mixture formed from esterified saturated C8- and C10-fatty acids. This mixture has the advantage that the saturated fatty acids provide improved stability of thelipid film and thus a surprisingly improved longer dwell time of the composition in the eye. One example of such a preferred medium chain triglyceride is Myritol®318.
[0081] The at least one ophthalmically acceptable oil and the at least one semifluorinated alkane may be present in the organic phase at a weight ratio of about 1:1 to about 4:1 , preferably about 3:1.
[0082] Similarly, the organic phase may comprise, by weight: about 20 to about 30% semifluorinated alkane and about 70 to about 80% ophthalmically acceptable oil. The organic phase may consist of, by weight: about 20 to about 30% semifluorinated alkane and about 70 to about 80% ophthalmically acceptable oil, preferably about 25% semifluorinated alkane and about 75% ophthalmically acceptable oil.
[0083] When the organic phase contains a mixture of at least one semifluorinated alkane and at least one ophthalmically acceptable oil, the organic phase may have a density of about 1.0 to about 1.1 g / cm3This may be achieved by using the ratios of semifluorinated alkane and ophthalmically acceptable oil described above. As described above, semifluorinated alkanes have a higher density than water (for example, F6H8 has a density of 1.334 g / cm3). Ophthalmically acceptable oils have lower densities than water. For example, the ophthalmically acceptable oil used in the examples below is an MCT with a density of 0.95 g / cm3. The density of an organic phase containing a mixture of semifluorinated alkane and ophthalmically acceptable oil is therefore closer to that of water than the density of an organic phase containing semifluorinated alkanes alone. Without wishing to be bound by theory, it is believed that a smaller density difference between the inner organic dispersed phase and the continuous outer aqueous phase improves the stability of the emulsion because the cream ing / sedimentation velocity of the dispersed droplets is lowered.
[0084] Providing an organic phase with a density of about 1.0 to about 1.1 g / cm3may therefore provide additional stability advantages for the emulsion. As shown in the examples, emulsions in which the organic phase contains semifluorinated alkane alone are surprisingly stable. However, even better stability is unexpectedly achieved using a blend of semifluorinated alkane and ophthalmically acceptable oil as the organic phase to achieve an organic phase density of about 1.0 to about 1.1 g / cm3(see Figure 1 ).
[0085] The organic phase may consist essentially of (i) F6H8, or (ii) a mixture of F6H8 and an ophthalmically acceptable oil such that the density is about 1.0 to about 1.1 g / cm3.
[0086] The emulsion may comprise about 0.05% to about 10% by weight of the organic phase and about 0.05% to about 10% by weight lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis. For example, the emulsion may comprise about 2% to about 8% by weight of the organic phase and about 2% to about 8% by weight lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis. Forexample, the emulsion may comprise about 5% by weight of the organic phase and about 5% by weight lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis.Further general features of the emulsion
[0087] The emulsion may have a viscosity of less than 5000 mPa s at 20°C, less than 350 mPa s at 20° C, less than 250 mPa s at 20° C, less than 200 mPa s at 20° C, less than 150 mPa s at 20° C, or less than 100 mPa s at 20° C. The viscosity is typically measured at 19.2 rpm. It is advantageous for the emulsion to have low viscosities within these ranges, for ease of application to the eye when applied as eye drops, as described above.
[0088] The emulsion of the invention typically has a negative Zeta potential, which is indicative of a stable emulsion. The emulsion may have a Zeta potential in the range of from about -2 mV to about -50 mV, for example from about -4 mV to about -25 mV.
[0089] The polydispersity index of the emulsion of the invention is typically less than about 0.5, for example from about 0.05 to about 0.5, for example about 0.05 to about 0.35. A low polydispersity index within these ranges is beneficial for stability because a lower PDI indicates a tighter droplet size distribution and this means that droplets are less likely to coalesce. Therefore, the described emulsions have particularly good stability properties due to their low PDIs.Preferred emulsion compositions
[0090] The emulsion may comprise from about 0.1 % to about 3% by weight of surfactant, from about 2% to about 8% by weight of I ifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis, and from about 2% to about 8% by weight F6H8. The emulsion may optionally further comprise from about 0.5% to about 2% by weight of osmoprotectant, preferably glycerin.
[0091] The emulsion may comprise from about 0.1% to about 3% by weight of ethylene oxide-formaldehyde-p-octylphenol copolymer, from about 2% to about 8% by weight of lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis, and from about 2% to about 8% by weight F6H8. The emulsion may optionally further comprise from about 0.5% to about 2% by weight of osmoprotectant, preferably glycerin.
[0092] The emulsion may comprise from about 0.1% to about 3% by weight of a polyethoxylated sorbitan fatty acid ester, for example polysorbate 80, from about 2% to about 8% by weight of lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis, and from about 2% to about 8% by weight F6H8. The emulsion may optionally further comprise from about 0.5% to about 2% by weight of osmoprotectant, preferably glycerin.
[0093] The emulsion may comprise from about 0.1% to about 3% by weight of a poloxamer, preferably poloxamer 188, from about 2% to about 8% by weight of lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis, and from about 2% to about 8% by weight F6H8. The emulsion may optionally further comprise from about 0.5% to about 2% by weight of osmoprotectant, preferably glycerin.
[0094] The emulsion may comprise from about 0.1% to about 3% by weight of cetalkonium chloride, from about 2% to about 8% by weight of lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis, and from about 2% to about 8% by weight F6H8. The emulsion may optionally further comprise from about 0.5% to about 2% by weight of osmoprotectant, preferably glycerin.
[0095] The emulsion may comprise from about 0.1 % to about 3% by weight of surfactant, wherein the surfactant is a combination of cetalkonium chloride and ethylene oxide-formaldehyde-p-octylphenol copolymer, from about 2% to about 8% by weight of lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis, and from about 2% to about 8% by weight F6H8. The emulsion may optionally further comprise from about 0.5% to about 2% by weight of osmoprotectant, preferably glycerin.
[0096] The emulsion may comprise from about 0.1 % to about 3% by weight of surfactant, wherein the surfactant is a combination of cetalkonium chloride and a polyethoxylated sorbitan fatty acid ester, for example polysorbate 80, from about 2% to about 8% by weight of lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis, and from about 2% to about 8% by weight F6H8. The emulsion may optionally further comprise from about 0.5% to about 2% by weight of osmoprotectant, preferably glycerin.Methods of treating ocular disorders
[0097] The invention also provides a method for the treatment or temporary prevention of at least one ocular disorder comprising administering to a patient in need thereof an effective amount of an emulsion disclosed herein.
[0098] The invention also provides an emulsion disclosed herein for use in a method for the treatment or temporary prevention of at least one ocular disorder, the method comprising administering to a patient in need thereof an effective amount of the emulsion.
[0099] The invention also provides the use of an emulsion disclosed herein in the manufacture of a medicament for use in a method for the treatment or temporary prevention of at least one ocular disorder, the method comprising administering to a patient in need thereof an effective amount of the emulsion.
[0100] Any of the emulsions described above may be used in the methods of the treatment or temporary prevention of at least one ocular disorder described herein.
[0101] The at least one ocular disorder may be dry eye disease. The ocular disorder may be evaporative dry eye disease or aqueous deficient dry eye disease. The ocular disorder may be evaporative dry eye disease and aqueous deficient dry eye disease. As explained above, the emulsions of the invention are particularly beneficial for treating mixed-type DED, where the patient has both evaporative DED and aqueous deficient DED.
[0102] The emulsion may be topically administered to the ocular surface of the patient, or topically administered to the cornea of the patient, or instilled into the conjunctival sac of the patient. The ophthalmic composition is preferably administered in the form of eye drops.
[0103] After application of eye drops, it can be useful to use nasolacrimal compression, obstruction, or occlusion (for example by applying compression to the lacrimal sac at the medial canthus). This procedure can reduce the amount of liquid entering the nasolacrimal duct and draining into the throat where they can lead to sensations of bad taste.
[0104] Proper dosages of the ophthalmic emulsions of the present disclosure are concentration-dependent. To determine the specific dose, a skilled artisan would have to take into account kinetics and absorption characteristics of the particular ingredients. In addition, the dosage may be dependent on the route of administration. The dosages may also be dependent on the degree of antibacterial and / or anti-inflammatory effect desired in a patient.
[0105] Methods of treating comprise administration of a daily dose of an ophthalmic emulsion of the present disclosure to a subject in need thereof. Determining and adjusting an appropriate dosing regimen (e.g., adjusting the number of doses and frequency of dosing) per day can be performed by one of ordinary skill in the relevant art, and will depend upon various factors such as the nature and progression of a disorder and / or condition associated with allergies and eye redness, the health, and / or age of the subject. The ophthalmic emulsions of the present disclosure may be administered to a patient in a single dose per day, in two doses per day, in three doses per day, in four doses per day, etc. up to, for example, ten doses per day. The composition may be administered to a patient for at least one week, at least two weeks, at least three weeks, at least one month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 12 months, at least one year, or for more than one year.
[0106] When using eye drops, one dose is typically a single droplet per eye. The emulsions disclosed herein may be used in a method of treatment of an ocular disorder, preferably DED, wherein the method comprises administering one drop to each eye of the patient once daily, twice daily, three times daily or four times daily. Twice daily dosingmay be particularly appropriate for emulsions of the invention, especially when used to treat DED.Container closure systems
[0107] The invention also provides a container closure system for dispensing an ophthalmic composition containing an emulsion disclosed herein, preferably wherein the container closure system is adapted to dispense the emulsion in the form of eye drops. Any of the emulsions described above may be included in the container closure systems disclosed herein.
[0108] The container closure system comprise a) a bottle or a vial and b) a dropper outlet for application of the emulsion to the eye. Such container closure systems are advantageous because they allow direct application of emulsions to the eye as eye drops, to treat ocular disorders, in particular DED.
[0109] The bottle or vial may be a multi-dose bottle or multi-dose vial. The multi-dose bottle or multi-dose vial may contain from about 4 to about 150 drops of the emulsion, for example from about 10 to about 60 drops of the emulsion.
[0110] The bottle or vial may contain from about 0.05 mL to about 3 mL of the emulsion, for example from about 0.1 mL to about 1 mL of the emulsion or from about 0.2 mL to about 0.6 mL of the emulsion.Methods of manufacture
[0111] The invention also provides a process for preparing an emulsion disclosed herein, comprising mixing the organic phase with the aqueous phase and emulsifying the organic phase and aqueous phase using high pressure homogenization, preferably wherein the high pressure homogenization takes place at a pressure of between about 100 bar and 2,000 bar.
[0112] Prior to the high pressure homogenization, the process may comprise emulsifying the organic phase and aqueous phase using high shear homogenization, preferably wherein the high shear homogenization takes place at between about 1,000 rpm and about 20,000 rpm.BRIEF DESCRIPTION OF THE DRAWINGS
[0113] Figure 1 shows accelerated stability testing of a marketed composition comprising 0.2 wt% MCT as the oil phase, and an emulsion comprising a blend of MCT and F6H8 as the oil phase.EXAMPLESExperimental methods
[0114] Osmolality: The osmolality of the prepared ophthalmic compositions can be measured at a temperature of 20°C with a micro-osmometer (Hermann Robling Messtechnik, Germany).
[0115] Viscosity: The viscosity of the prepared ophthalmic compositions can be measured at 19.2 rpm and 20°C, preferably by the cone-plate method, using for example a Wells Brookfield cone-plate viscometer of the type DV-III+ (Brookfield Engineering Laboratories Vertribut GmbH, Germany) with a CP51 spindle.
[0116] Measurement of organic phase droplet size: The Z-average droplet size of the dispersed organic phase can be measured by dynamic light scattering (DLS) at 25 °C, using a particle size analyser (e.g. Malvern Zetasizer Pro Red, Malvern Instruments, Malvern, UK). Each sample may be added into a 12mm square disposable polystyrene cuvette and fixed in the direction of laser light beam. The signal of the scattered light can be measured, and the droplet sizes determined based on the physical properties of the scattered light. The integrated software, for example from Malvern, can then be used to evaluate the results.
[0117] PPI: The PDI of the dispersed organic phase can be measured by dynamic light scattering (DLS) at 25 °C, using a particle size analyser (e.g. Malvern Zetasizer Pro Red, Malvern Instruments, Malvern, UK). The PDI can be determined from the particle size distribution output obtained from DLS. For example, each sample may be added into a 12mm square disposable polystyrene cuvette and fixed in the direction of laser light beam. The signal of the scattered light can be measured, and the droplet sizes determined based on the physical properties of the scattered light. The integrated software, for example from Malvern, can then be used to evaluate the results.
[0118] Zeta potential: Zeta potential can be determined by dynamic light scattering (DLS) at 25 °C, using a particle size analyser (e.g. Malvern Zetasizer Pro Red, Malvern Instruments, Malvern, UK). For example, Zeta potential can be measured using Folded Capillary Zeta Cells and undiluted samples at 25 °C. The integrated software, for example from Malvern, can be used to evaluate the results.
[0119] Molecular weight, Mw: Mw can be determined by size exclusion chromatography, specifically gel permeation chromatography (GPC), with a monodisperse polystyrene equivalent molecular weight calibration standard and GPC columns (manufactured by PSS, applied column combination: SDV 5pm 1000A, SDV 5pm 500A, SDV 5pm 100A). The flow rate in the columns may be 1.0 ml / min, eluent: tetrahydrofuran, column temperature: 40°C, a differential refractive index detector (Rl)and a UV-detector (254nm) may be used. Unless otherwise stated, the molecular weight is the number average molecular weight.Example emulsions
[0120] The following example emulsions were prepared as set out in Tables 1-5, and characterized. Characterizing data for each emulsion is set out in Tables 6-13.
[0121] The F6H8 used in the following examples consisted essentially of 1 -perfluorohexyloctane and less than 0.5% (w / w) of 2-perfluorohexyloctane. The F6H8 was provided as Miebo™.
[0122] The exemplified emulsions are intended to be administered as eye drops for use in DED therapy.Table 1: Compositions 1, 2 and 3, with 5% F6H8, 5% Lifitegrast and tyloxapol, or a combination of tyloxapol and cetalkonium chloride, as surfactant.Composition 1 Composition 2 Composition 3 Component % w / w % w / w % w / wTyloxapol 1 1 1Cetalkonium chloride 0.02 0.01 - Glycerol 86% 1.16 1.16 1.16Sodium thiosulfate 0.3 0.3 0.3pentahydrateSodium 0.896 0.896 0.896 monohydrogenphosphatedodecahydrateLifitegrast 5 5 5F6H8 5 5 5NaOH (solid) 0.308 0.308 0.3081 N NaOH solution q.s. q.s. q.s.1 N HCI solution q.s. q.s. q.s.WFI Ad 100 Ad 100 Ad 100Process High Pressure High Pressure High Pressure Homogenizer at Homogenizer Homogenizer 800 bar for 5 at 1500 bar for at 800 bar for 5cycles 3 cycles cyclesTable 2: Compositions 4 and 5, with 5% F6H8, 5% Lifitegrast and polysorbate 80, or a combination of polysorbate 80 and cetalkonium chloride, as surfactant.Composition 4Composition 5Component % w / w % w / wPolysorbate 80 1 1Cetalkonium chloride 0.01 -Glycerol 86% 1.16 1.16Sodium thiosulfate pentahydrate 0.3 0.3Sodium monohydrogenphosphate 0.896 0.896dodecahydrateLifitegrast 5 5F6H8 5 5NaOH (solid) 0.308 0.3081 N NaOH solution q.s. q.s.1 N HCI solution q.s. q.s.WFI Ad 100 Ad 100Process Magnetic stirring and High shear then high Pressure homogenisation at Homogenizer at 11000 rpm and then High 1500 bar for 3 cycles Pressure Homogenizerat 2000 bar for 3 cyclesTable 3: Composition 6 with 5% F6H8, 5% Lifitegrast and poloxamer 188 as surfactant. Component % w / wPoloxamer 188 2Glycerol 86% 1.16Sodium thiosulfate pentahydrate 0.3Sodium monohydrogenphosphate 0.896dodecahydrateLifitegrast 5F6H8 5NaOH (solid) 0.3081 N NaOH solution q.s.1 N HCI solution q.s.WFI Ad 100Process High shear homogenisation at 11800 rpm and then High Pressure Homogenizer at 2000 bar for3 cyclesTable 4: Composition 7 with 5% F6H8, 5% Lifitegrast and cetalkonium chloride as surfactant.Component % w / wCetalkonium chloride 0.1Glycerol 86% 1.16Sodium thiosulfate pentahydrate 0.3Sodium monohydrogenphosphate 0.896dodecahydrateLifitegrast 5F6H8 5NaOH (solid) 0.3081 N NaOH solution q.s.1 N HCI solution q.s.WFI Ad 100Process High shear homogenisation at 19000 rpm and then High Pressure Homogenizer at 2000 bar for3 cyclesTable 5: Composition 8 with 5% F6H8, 5% Lifitegrast and lecithin S75 as surfactant. Component % w / wLecithin S75 (Lipoid S75: a soybean 3phospholipid S75)Glycerol 86% 1.16Sodium thiosulfate pentahydrate 0.3Sodium monohydrogenphosphate 0.896dodecahydrateLifitegrast 5F6H8 51 N NaOH solution q.s.0,1N HCI solution q.s.WFI Ad 100Process High shear homogenisation at 6800 rpm and then High Pressure Homogenizer at 2000 bar for3 cyclesTable 6: Droplet size characterization of composition 1Parameter Mean Standard RSD (%)DeviationZ-average (nm) 76.2 1.936 2.541Peak 1 Mean by 97.47 1.834 1.882intensity ordered byarea (nm)Polydispersity index 0.257 0.01083 4.215Zeta potential (mV) -11.97 1.134 9.467Table 7: Droplet size characterization of composition 2Parameter Mean Standard RSD (%)DeviationZ-average (nm) 97.98 2.207 2.252 Peak 1 Mean by 116.4 3.147 2.704 intensity ordered byarea (nm)Polydispersity index 0.2294 0.009748 4.249Zeta potential (mV) -15.25 1.477 9.688Table 8: Droplet size characterization of composition 3 Parameter Mean Standard RSD (%)DeviationZ-average (nm) 79.45 0.8718 1.097 Peak 1 Mean by 94.05 9.066 9.64 intensity ordered byarea (nm)Polydispersity index 0.3346 0.02233 6.673Zeta potential (mV) -12.09 0.6447 5.331Table 9: Droplet size characterization of composition 4 Parameter Mean Standard RSD (%)DeviationZ-average (nm) 97.48 1.854 1.902 Peak 1 Mean by 113.4 1.095 0.9653 intensity ordered byarea (nm)Polydispersity index 0.1663 0.0177 10.65Zeta potential (mV) -8.73 2.636 30.2Table 10: Droplet size characterization of composition 5 Parameter Mean Standard RSD (%)DeviationZ-average (nm) 89.68 1.986 2.215 Peak 1 Mean by 106.6 3.532 3.314 intensity ordered byarea (nm)Polydispersity index 0.1838 0.01688 9.184 Zeta potential (mV) -4.541 1.143 25.16Table 11: Droplet size characterization of composition 6 Parameter Mean Standard RSD (%)DeviationZ-average (nm) 179.3 4.638 2.586Peak 1 Mean by 193.3 3.649 1.887intensity ordered byarea (nm)Polydispersity index 0.07177 0.01234 17.19Zeta potential (mV) -4.817 0.5265 10.93Table 12: Droplet size characterization of composition 7Parameter Mean Standard RSD (%)DeviationZ-average (nm) 384.6 7.763 2.018Peak 1 Mean by 444 4.981 1.122intensity ordered byarea (nm)Polydispersity index 0.1707 0.008981 5,261Zeta potential (mV) -24.46 2.325 9.504Table 13: Droplet size characterization of composition 8Parameter MeanZ-average (nm) 48Polydispersity index 0.48Zeta potential (mV) -3.0
[0123] A nanoemulsion could be formed with all of compositions 1-8. However, for the emulsion containing the amphoteric surfactant lecithin S75 (composition 8), it was observed that particle formation occurred quite soon after preparation due to aggregation of oil phase droplets, indicating instability. When a similar emulsion containing the amphoteric surfactant lecithin S100 was made, particle formation occurred even more quickly than with composition 8, indicating that the emulsion containing lecithin S100 was even less stable than composition 8 containing lecithin S75. This observation of particle formation was not made for compositions 1-7, containing nonionic and / or cationic surfactants, demonstrating that nonionic and / or cationic surfactants lead to improved emulsion stability.
[0124] The relative instability observed for composition 8 relative to compositions 1-7 is supported by the characterization data in Tables 6-13. In particular, the Zeta potential of composition 8 (-3.0 mV) was closer to zero than for compositions 1-7 (range of -4.541 to -24.46), indicating lower stability for composition 8. In addition, the PDI of composition 8 (0.48) was higher than for compositions 1 -6 (range of 0.07177-0.3346), again indicating lower stability and a higher propensity for droplet aggregation for composition 8.Stability testing
[0125] As described above, the inventors have surprisingly found that using appropriate organic component blends can result in a density of the inner organic phase closer to that of water, which can support the stability of the emulsion. In this way, the inventors have found that mixtures of F6H8 or other semifluorinated alkanes with ophthalmically acceptable oils have additional benefits in terms of physical stability. Oils such as MCT and mineral oil have a much lower density than of pure F6H8. For example, F6H8 has a density of 1.334 g / cm3, and the MCT Myritol®318 has a density of 0.95 g / cm3
[0126] Stability testing was performed to compare the accelerated stability of two emulsions: (i) a marketed formulation with 0.2 wt% organic phase comprising only MCT (Table 8 below) and (i) an emulsion with 0.2 wt% organic phase comprising a blend of F6H8 and MCT to result in a density of 1 (Table 9 below).Table 8: Marketed emulsion, with 0.2 wt% organic phase comprising MCT only Component Concentration (wt%)Carbomer (Carbopol 980, polyacrylic 0.0625acid polymer)Sodium hyaluronate 0.2400Glycerin 85% 2.9000NaOH 0.0231MCT (Myritol 318) 0.2000Water for injection Ad. 100Table 9: Emulsion with 0.2 wt% organic phase comprising a blend of F6H8 and MCT (Myritol 318)Component Concentration Amount (kg, 100(mg / mL) kg batch size) Hyaluronic acid 2.400 0.2400Organic Phase 2.000 0.2000(MCT / F6H8 in a weightratio of 3:1)Carbopol 980 NF 0.625 0.0625Glycerine (85%) 29.000 2.9000NaOH 5.400 0.5400Water for injection (WFI) ad 1mL ad 100 kg
[0127] The systems were tested by analyzing the light transmission of the samples during high-speed centrifugation (using a photo centrifuge analyser, LUMiFuge®) and the measured instability index of each system was compared. The instability index is based on the particle concentration change in the emulsions, which may occur e.g., during creaming or sedimentation. The closer the instability index to 1 , the higher the instability of the system. With an instability index of 1 , there is no particle concentration change due to accumulation or sedimentation.
[0128] As shown in Figure 1, the formulations where the inner organic phase was modified by blending F6H8 with MCT to reach a density of 1 (Table 9) showed much higher stability than systems where the inner organic phase contained only MCT.NUMBERED EMBODIMENTS
[0129] The invention provides the following numbered embodiments.
[0130] 1. An emulsion for ocular applications, comprising:an organic phase comprising at least one semifluorinated alkane;an aqueous phase comprising lifitegrast, or a pharmaceutically acceptable salt thereof; anda surfactant;wherein the emulsion comprises less than 29% by weight of the organic phase.
[0131] 2. The emulsion of embodiment 1, wherein the surfactant is selected from an anionic surfactant, a cationic surfactant, a nonionic surfactant, an amphoteric surfactant, or a combination thereof.
[0132] 3. The emulsion of embodiment 1 or embodiment 2, wherein the surfactant is selected from a cationic surfactant, a nonionic surfactant, or a combination thereof.
[0133] 4. The emulsion of embodiment 3, wherein the surfactant is selected from ethylene oxide-formaldehyde-p-octylphenol copolymer, polyethoxylated sorbitan fatty acid esters such as polysorbate 20 or polysorbate 60 or polysorbate 80, poloxamers such as poloxamer 188, benzalkonium chloride, cetyltrimethylammonium bromide, and cetalkonium chloride, or a combination thereof.
[0134] 5. The emulsion of embodiment 4, wherein the surfactant is selected from ethylene oxide-formaldehyde-p-octylphenol copolymer, poloxamers such as poloxamer 188, and cetalkonium chloride, or a combination thereof.
[0135] 6. The emulsion of any preceding embodiment, wherein the surfactant is a combination of a cationic surfactant and a nonionic surfactant.
[0136] 7. The emulsion of embodiment 6, wherein the cationic surfactant is cetalkonium chloride and the nonionic surfactant is ethylene oxide-formaldehyde-p-octylphenol copolymer or a polyethoxylated sorbitan fatty acid ester such as polysorbate 80.
[0137] 8. The emulsion of any preceding embodiment, wherein the emulsion comprises a surfactant with an HLB value of at least 5, preferably at least 10, more preferably at least 12.
[0138] 9. The emulsion of any preceding embodiment, wherein the emulsion is an oil in water emulsion.
[0139] 10. The emulsion of embodiment 9, wherein the emulsion is a nanoemulsion, optionally wherein the Z-average size of the inner organic phase droplets is in the range of from about 40 to about 500 nm, for example from about 70 to about 400 nm, for example from about 70 to about 220 nm.
[0140] 11. The emulsion of embodiment 9 or embodiment 10, wherein the polydispersity index of the emulsion is less than about 0.5, for example from about 0.05 to about 0.5, for example about 0.05 to about 0.35.
[0141] 12. The emulsion of any preceding embodiment, wherein emulsion comprises about 0.05% to about 10% by weight of lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis, for example about 2% to about 8% by weight of lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis, for example about 5% by weight of lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis.
[0142] 13. The emulsion of any preceding embodiment, wherein the lifitegrast is in the form of lifitegrast free acid.
[0143] 14. The emulsion of any preceding embodiment, wherein the at least one semifluorinated alkane comprises F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof.
[0144] 15. The emulsion of any preceding embodiment, wherein the at least one semifluorinated alkane comprises F4H5, F4H6, F5H6, F5H7, F6H6, F6H7, F6H8, F6H10, or any combination thereof; preferably F6H8, F6H10, or a combination thereof.
[0145] 16. The emulsion of any preceding embodiment, wherein the at least one semifluorinated alkane is selected from F4H5, or F6H8, or a combination thereof.
[0146] 17. The emulsion of any preceding embodiment, wherein the at least one semifluorinated alkane comprises F6H8, optionally wherein the organic phase is substantially free of other semifluorinated alkanes.
[0147] 18. The emulsion of any preceding embodiment, wherein F6H8 is the only semifluorinated alkane in the organic phase.
[0148] 19. The emulsion of any one of embodiments 1-16, wherein the at least one semifluorinated alkane comprises F4H5, optionally wherein the organic phase is substantially free of other semifluorinated alkanes.
[0149] 20. The emulsion of embodiment 19, wherein F4H5 is the only semifluorinated alkane in the organic phase.
[0150] 21. The emulsion of any preceding embodiment, wherein the emulsion comprises less than about 25% by weight of the organic phase, for example less than about 20% by weight or less than about 15% by weight.
[0151] 22. The emulsion of any preceding embodiment, wherein the emulsion comprises about 0.05% to about 10% by weight of the organic phase, for example about 2% to about 8% by weight of the organic phase, for example about 5% by weight of the organic phase.
[0152] 23. The emulsion of any preceding embodiment, wherein the emulsion comprises about 0.05% to about 10% by weight of the organic phase and about 0.05% to about 10% by weight I if itegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis;for example about 2% to about 8% by weight of the organic phase and about 2% to about 8% by weight lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis;for example about 5% by weight of the organic phase and about 5% by weight lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis.
[0153] 24. The emulsion of embodiment 23, wherein the organic phase consists essentially of semifluorinated alkane, preferably wherein said semifluorinated alkane is F6H8.
[0154] 25. The emulsion of any preceding embodiment, wherein the organic phase comprises at least 90% by weight semifluorinated alkane, for example wherein the organic phase consists essentially of semifluorinated alkane.
[0155] 26. The emulsion of embodiment 25, wherein the organic phase comprises at least 90% by weight F6H8, for example wherein the organic phase consists essentially of F6H8.
[0156] 27. The emulsion of any preceding embodiment, wherein the emulsion comprises an osmoprotectant.
[0157] 28. The emulsion of embodiment 27, wherein the osmoprotectant is selected from dextrose, glycerin, propylene glycol, sorbitol, mannitol, urea, polyethylene glycol, boric acid, magnesium sulfate, zinc sulfate, sodium chloride, potassium chloride, calciumchloride, sodium sulfate, sodium hydrogen phosphate, trisodium citrate, trisodium phosphate, and mixtures thereof, preferably wherein the osmoprotectant is glycerin.
[0158] 29. The emulsion of embodiment 27, wherein the emulsion comprises from about 0.5% to about 5% by weight of glycerin, for example from about 0.5% to about 2% by weight of glycerin.
[0159] 30. The emulsion of any preceding embodiment, wherein the emulsion has an osmolality of from about 250 to about 350 mOsm / kg.
[0160] 31. The emulsion of any preceding embodiment, wherein the emulsion comprises a preservative.
[0161] 32. The emulsion of embodiment 31 , wherein the preservative is selected from sodium thiosulfate, benzalkonium chloride, cetrimonium, sodium perborate, stabilized oxychloro complex, a composition containing boric acid, sorbitol, propylene glycol, and zinc chloride, polyquaternium-1, chlorobutanol, edetate disodium, polyhexamethylene biguanide, or combinations thereof, preferably wherein the preservative is sodium thiosulfate.
[0162] 33. The emulsion of embodiment 31 or 32, wherein the preservative is present in an amount of from about 0.1% to about 0.5% by weight of the emulsion, for example from about 0.2% to about 0.4% by weight of the emulsion, for example about 0.3% by weight of the emulsion.
[0163] 34. The emulsion of any preceding embodiment, wherein the pH of the emulsion is between about 6 and about 9.
[0164] 35. The emulsion of embodiment 34, comprising a buffer system, for example a phosphate or citrate buffer, to maintain the pH of the emulsion between about 6 and about 9.
[0165] 36. The emulsion of any preceding embodiment, wherein the emulsion has a negative Zeta potential, for example a Zeta potential of about -2 to about -50, for example about -4 to about -25.
[0166] 37. The emulsion of any preceding embodiment, wherein the emulsion has a viscosity of less than about 5000 mPa*s at 20°C, optionally less than about 350 mPa s at 20°C.
[0167] 38. The emulsion of any one of embodiments 1-23 and 27-37 wherein the organic phase additionally comprises at least one ophthalmically acceptable oil, preferably wherein the ophthalmically acceptable oil is selected from triglycerides and mineral oil, for example a medium-chain triglyceride.
[0168] 39. The emulsion of embodiment 38, wherein the at least one ophthalmically acceptable oil and the at least one semifluorinated alkane are present in the organic phase at a weight ratio of about 1 : 1 to about 4: 1 , for example about 3: 1.
[0169] 40. The emulsion of embodiment 38 or embodiment 39, wherein the organic phase has a density of about 1.0 to about 1.1 g / cm3
[0170] 41. The emulsion of any preceding embodiment, wherein the total amount of surfactant in the emulsion is in the range of from about 0.05% to about 5% by weight, for example from about 0.1% to about 3% by weight, or from about 0.1% to about 2% by weight.
[0171] 42. The emulsion of any preceding embodiment, wherein the emulsion comprises about 2% to about 8% by weight of the organic phase and the total amount of surfactant in the emulsion is in the range of from about 0.1% to about 4% by weight, for example in the range of from about 0.1 % to about 2% by weight.
[0172] 43. A method for the treatment or temporary prevention of at least one ocular disorder comprising administering to a patient in need thereof an effective amount of the emulsion of any preceding embodiment.
[0173] 44. The method of embodiment 43, wherein the at least one ocular disorder is dry eye disease.
[0174] 45. The method of embodiment 44, where the at least one ocular disorder is evaporative dry eye disease or aqueous deficient dry eye disease.
[0175] 46. The method of embodiment 44, wherein the at least one ocular disorder is evaporative dry eye disease and aqueous deficient dry eye disease.
[0176] 47. The method according to any one of embodiments 43 to 46, wherein the emulsion is topically administered to the ocular surface of the patient, or topically administered to the cornea of the patient, or instilled into the conjunctival sac of the patient.
[0177] 48. The method according to any one of embodiments 43-47, wherein the emulsion is administered in the form of eye drops.
[0178] 49. A container closure system for dispensing an ophthalmic composition in the form of eye drops, wherein the container closure system contains the emulsion of any one of embodiments 1-42.
[0179] 50. The container closure system of embodiment 49, wherein the container closure system comprises a) a bottle or vial and b) a dropper outlet for application of the emulsion to the eye.
[0180] 51. The container closure system of embodiment 50, wherein the bottle or vial is a multi-dose bottle or multi-dose vial.
[0181] 52. The container closure system of embodiment 51 , wherein the bottle or vial contains from about 4 to about 150 drops of the emulsion, for example from about 10 to about 60 drops of the emulsion.
[0182] 53. The container closure system of any one of embodiments 49-52, wherein the bottle or vial contains from about 0.05 mL to about 3 mL of the emulsion, for example from about 0.1 mL to about 1 mL of the emulsion or from about 0.2 mL to about 0.6 mL of the emulsion.
[0183] 54. A process for preparing the emulsion of any one of embodiments 1-42, comprising mixing the organic phase with the aqueous phase and emulsifying the organic phase and aqueous phase using high pressure homogenization, preferably wherein the high pressure homogenization takes place at a pressure of between about 100 bar and about 2,500 bar.
[0184] 55. The process of embodiment 54, wherein, prior to the high pressure homogenization, the process further comprises emulsifying the organic phase and aqueous phase using high shear homogenization, preferably wherein the high shear homogenization takes place at between about 1 ,000 rpm and about 20,000 rpm.
[0185] It will be understood that the inventors’ work has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.
Claims
CLAIMS1. An emulsion for ocular applications, comprising:an organic phase comprising at least one semifluorinated alkane;an aqueous phase comprising lifitegrast, or a pharmaceutically acceptable salt thereof; anda surfactant;wherein the emulsion comprises less than 29% by weight of the organic phase.
2. The emulsion of claim 1, wherein the surfactant is selected from an anionic surfactant, a cationic surfactant, a nonionic surfactant, an amphoteric surfactant, or a combination thereof.
3. The emulsion of claim 1 or claim 2, wherein the surfactant is selected from a cationic surfactant, a nonionic surfactant, or a combination thereof.
4. The emulsion of claim 3, wherein the surfactant is selected from ethylene oxide-formaldehyde-p-octylphenol copolymer, polyethoxylated sorbitan fatty acid esters such as polysorbate 20 or polysorbate 60 or polysorbate 80, poloxamers such as poloxamer 188, benzalkonium chloride, cetyltrimethylammonium bromide, and cetalkonium chloride, or a combination thereof.
5. The emulsion of claim 4, wherein the surfactant is selected from ethylene oxide-formaldehyde-p-octylphenol copolymer, poloxamers such as poloxamer 188, and cetalkonium chloride, or a combination thereof.
6. The emulsion of any preceding claim, wherein the surfactant is a combination of a cationic surfactant and a nonionic surfactant.
7. The emulsion of any preceding claim, wherein the emulsion comprises a surfactant with an HLB value of at least 5, preferably at least 10, more preferably at least 12.
8. The emulsion of any preceding claim, wherein the emulsion is an oil in water emulsion.
9. The emulsion of any preceding claim, wherein the at least one semifluorinated alkane comprises F4H4, F4H5, F4H6, F4H7, F4H8, F5H4, F5H5, F5H6, F5H7, F5H8, F6H2, F6H4, F6H6, F6H7, F6H8, F6H9, F6H10, F6H12, F8H8, F8H10, F8H12, F10H10, or any combination thereof.
10. The emulsion of any preceding claim, wherein emulsion comprises about 0.05% to about 10% by weight of I if itegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis, for example about 2% to about 8% by weight of lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis, for example about 5% by weight of lifitegrast, or a pharmaceutically acceptable salt thereof, on a free acid basis.
11. The emulsion of any preceding claim, wherein the at least one semifluorinated alkane is selected from F4H5, F6H8, or a combination thereof.
12. The emulsion of any preceding claim, wherein F6H8 is the only semifluorinated alkane in the organic phase.
13. The emulsion of any preceding claim, wherein the emulsion comprises about 0.05% to about 10% by weight of the organic phase, for example about 2% to about 8% by weight of the organic phase, for example about 5% by weight of the organic phase.
14. The emulsion of any preceding claim, wherein the organic phase consists essentially of semifluorinated alkane, preferably wherein said semifluorinated alkane is F6H8.
15. The emulsion of any preceding embodiment, wherein the emulsion comprises an osmoprotectant, optionally wherein the osmoprotectant is selected from dextrose, glycerin, propylene glycol, sorbitol, mannitol, urea, polyethylene glycol, boric acid, magnesium sulfate, zinc sulfate, sodium chloride, potassium chloride, calcium chloride, sodium sulfate, sodium hydrogen phosphate, trisodium citrate, trisodium phosphate, and mixtures thereof, preferably wherein the osmoprotectant is glycerin.
16. The emulsion of any one of claims 1-13 or 15 wherein the organic phase additionally comprises at least one ophthalmically acceptable oil, preferably wherein the ophthalmically acceptable oil is selected from triglycerides and mineral oil, for example a medium-chain triglyceride.
17. The emulsion of claim 16, wherein the at least one ophthalmically acceptable oil and the at least one semifluorinated alkane are present in the organic phase at a weight ratio of about 1 :1 to about 4:1 , for example about 3:1.
18. The emulsion of claim 16 or claim 17, wherein the organic phase has a density of about 1.0 to about 1.1 g / cm319. The emulsion of any preceding embodiment, wherein the emulsion comprises about 2% to about 8% by weight of the organic phase and the total amount of surfactant in the emulsion is in the range of from about 0.1% to about 4% by weight, for example in the range of from about 0.1 % to about 2% by weight.
20. The emulsion of any preceding claim, for use in a method for the treatment or temporary prevention of at least one ocular disorder, wherein the method comprises administering to a patient in need thereof an effective amount of said emulsion.
21. The emulsion for use according to claim 20, wherein the at least one ocular disorder is dry eye disease.
22. The emulsion for use according to claim 20 or claim 21, wherein the at least one ocular disorder is evaporative dry eye disease and / or aqueous deficient dry eye disease.
23. A container closure system for dispensing an ophthalmic composition in the form of eye drops, wherein the container closure system contains the emulsion of any one of claims 1-19.
24. A process for preparing the emulsion of any one of claims 1-19, comprising mixing the organic phase with the aqueous phase and emulsifying the organic phase and aqueous phase using high pressure homogenization, preferably wherein the high pressure homogenization takes place at a pressure of between about 100 bar and about 2,500 bar.
25. The process of claim 24, wherein, prior to the high pressure homogenization, the process further comprises emulsifying the organic phase and aqueous phase using highshear homogenization, preferably wherein the high shear homogenization takes place atbetween about 1 ,000 rpm and about 20,000 rpm.
